Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax

Aziz, Mehar; Singh, Samer; Kumar, P. Anand; Bhatnagar, Rakesh

doi:10.1016/s0006-291x(02)02625-6

Cited by 66 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Koya et al (2005) published for the first time the PA expression in plants from stable nucleartransgenic tobacco. Aziz et al (2002) also reported the expression of PA in leaves of stable nuclear-transgenic tomato plants. Expression of PA in tobacco or tomato was enhanced in combination with a second B. anthracis protein, lethal factor (LF), and showing cytolytic activity when applied to macrophage-like cell lines.…”

Section: Anthraxmentioning

confidence: 97%

Transgenic plants as green factories for vaccine production

Kumar¹,

Raja²,

Wani³

et al. 2013

Afr. J. Biotechnol.

View full text Add to dashboard Cite

Edible vaccine technology represents an alternative to fermentation based vaccine production system. Transgenic plants are used for the production of plant derived specific vaccines with native immunogenic properties stimulating both humoral and mucosal immune responses. Keeping in view the practical need of new technology for production and delivery of inexpensive vaccines, especially in developing world, plant derived edible vaccines is the best option in hand to combat infectious diseases. Plant derived vaccine is easy to administer, cost effective, readily acceptable, have increased safety, stability, versatility and efficacy. Several plant derived vaccines are under research, some are under clinical trials for commercial use. Like most biotechnology products, the IP situation for edible vaccines is complex as IP rights influence every stage of vaccine development.

show abstract

Section: Anthraxmentioning

confidence: 97%

Transgenic plants as green factories for vaccine production

Kumar¹,

Raja²,

Wani³

et al. 2013

Afr. J. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…The first protective antigen expression from stable nuclear recombinent tobacco was published by Koya et al [96]. The researcher named Aziz also worked on the same topic and noted the expression of protective antigen of stable transgenic nucleus in the leaves of tomato [97]. Protective antigen which was expressed in tomato or tobacco was developed by combining with a second B. anthracis lethal factor which was protein in nature, and which showed cytoplasmic breaking activity after it was applied to cell lines similar to macrophages.…”

Section: Anthraxmentioning

confidence: 99%

“…When tomato leaf was innoculated into mice, antisera with neutralizing activity against anthrax lethal toxin can be recovered. The antisera was a combination of lethal factor and protective antigen [97].…”

Section: Anthraxmentioning

confidence: 99%

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

2016

J Coast Life Med

View full text Add to dashboard Cite

“…Prior studies did not investigate functionality of plant-derived PA in animal studies (3,30). The production of anti-PA IgG antibodies combined with in vitro neutralization and toxin challenge studies shows that immunization with transgenic chloroplast-derived PA is highly effective.…”

Section: Vol 73 2005 Effects Of Plant-based Anthrax Vaccination In mentioning

confidence: 99%

Plant-Based Vaccine: Mice Immunized with Chloroplast-Derived Anthrax Protective Antigen Survive Anthrax Lethal Toxin Challenge

et al. 2005

View full text Add to dashboard Cite

The currently available human vaccine for anthrax, derived from the culture supernatant of Bacillus anthracis, contains the protective antigen (PA) and traces of the lethal and edema factors, which may contribute to adverse side effects associated with this vaccine. Therefore, an effective expression system that can provide a clean, safe, and efficacious vaccine is required. In an effort to produce anthrax vaccine in large quantities and free of extraneous bacterial contaminants, PA was expressed in transgenic tobacco chloroplasts by inserting the pagA gene into the chloroplast genome. Chloroplast integration of the pagA gene was confirmed by PCR and Southern analysis. Mature leaves grown under continuous illumination contained PA as up to 14.2% of the total soluble protein. Cytotoxicity measurements in macrophage lysis assays showed that chloroplast-derived PA was equal in potency to PA produced in B. anthracis. Subcutaneous immunization of mice with partially purified chloroplast-derived or B. anthracis-derived PA with adjuvant yielded immunoglobulin G titers up to 1:320,000, and both groups of mice survived (100%) challenge with lethal doses of toxin. An average yield of about 150 mg of PA per plant should produce 360 million doses of a purified vaccine free of bacterial toxins edema factor and lethal factor from 1 acre of land. Such high expression levels without using fermenters and the immunoprotection offered by the chloroplast-derived PA should facilitate development of a cleaner and safer anthrax vaccine at a lower production cost. These results demonstrate the immunogenic and immunoprotective properties of plant-derived anthrax vaccine antigen.

show abstract

Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax

Cited by 66 publications

References 31 publications

Transgenic plants as green factories for vaccine production

Transgenic plants as green factories for vaccine production

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

Plant-Based Vaccine: Mice Immunized with Chloroplast-Derived Anthrax Protective Antigen Survive Anthrax Lethal Toxin Challenge

Contact Info

Product

Resources

About